Figures computed from official regulatory filings — .
Analysttarget 19,000 USD (+3745218%)
Ownershipinsiders 0% · institutions 3.48% · short 2.4% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for RedHill Biopharma Ltd. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Market information source · Oct 19, 2026
SEC company identity · Oct 19, 2026
Open-market timeline · full history
3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Raday Gilead | Sell | $1.4K | SEC |
| Raday Gilead | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Raday Gilead | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Raday Gilead | Sell | $1.4K | SEC |
| Raday Gilead | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Raday Gilead | Sell | $1.6K | SEC |